trending Market Intelligence /marketintelligence/en/news-insights/trending/i9ajg88zdrhsc1ddkzcizw2 content esgSubNav
In This List

Sesen Bio president/CEO steps down; replacement named


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Sesen Bio president/CEO steps down; replacement named

Cambridge, Mass.-based Sesen Bio Inc. said President and CEO Stephen Hurly left the company on Aug. 7.

The board appointed Thomas Cannell to serve as president, CEO and as a class I director.

Cannell served as executive vice president, COO and president of global commercial products at Orexigen Therapeutics Inc. from June 2016 to July 2018. Cannell worked at Merck & Co. Inc. for 27 years, in sales and marketing and as a general manager. His most recent position at Merck was head of global human health operating model team.

Further, Abbie Celniker and Paul Chaney resigned from the board. Their resignations were not due to any disagreement with the company.

With Cannell's appointment to the board and the resignations of Celniker and Chaney, Sesen Bio's board was reduced to seven members from eight.

Sesen Bio develops therapies for patients with cancer.